As per our report, the global cancer immunotherapy market size is forecasted to grow at a CAGR of 12.52% from 2021 to 2026. This market is forecasted to worth USD 178.5 billion by 2026 from USD 99.02 billion in 2021.
Immunotherapy, which is also known as biologic therapy, can be performed in two ways. That is by stimulating one’s immune system to fight against the disease by attacking defective cancer cells and giving constituents of the immune system from outside such as synthetic proteins into the body to fight against the disease. It is performed to treat cancer patients for a long time, even when doctors do not thoroughly understand the immune system. Immunotherapy is a treatment option that uses certain parts of an immune system to fight against various diseases such as cancer.
Cancer immunotherapy is a type of therapy used to treat various cancer diseases that involves stimulation and suppression of the immune system. It is made of white blood cells, organs, and tissue of the lymphatic system. Several companies are investing massive amounts in the treatment of cancer. Currently, U.S. food and administration has approved 32 various immunotherapies to treat 20 cancer types, including cell-based immunotherapies, immunomodulators, BCG vaccines, targeted therapies, and oncotic viruses.
Impact of COVID-19 on the cancer immunotherapy market:
COVID-19 has a positive impact on the healthcare sector. World health organization announced the COVID-19 as a pandemic on March 11, 2020. During the first half of 2020, the cancer immunotherapy market was slightly reduced due to the lockdown restrictions and ban on travel. There was an increase in the cancer patient rate, but the world was focused on fighting against coronavirus, many cancer treatments have been postponed. As there is a high risk for cancer patients due to COVID 19, they need to stay home. The treatment procedures for the cancer patients were resumed from the last months with the preventive measures as it is mandatory to give continuous treatment for the cancer patients. The market shares are expected to grab the highest growth rate by 2021.
Multiple therapeutic regimens are being followed across various countries to come up with reliable cancer treatment. Immunotherapy is a type of cancer treatment that boosts the human immune system to fight against cancer cells. But cancer treatment therapies have been stopped and postponed by various hospitals worldwide due to the sudden outburst of the COVID-19 pandemic. Many countries have been impacted negatively by coronavirus. No activities related to cancer therapies have been done due to the unavailability of doctors and medical centers, but the cancer patients need to have surveillance on the conditions regularly. This is expected to result in industry growth over the forecast period.
MARKET DRIVERS:
The growing occurrence of cancer, the rising number of R & D, and technological developments in treatment options are majorly fuelling the global cancer immunotherapy market.
Cancer has now become one of the leading causes of death throughout the world. According to the statistics published by the World Health Organization (WHO), an estimated 9.6 million were died of cancer in the year 2018 and also found tobacco as the leading risk factor for cancer and recorded 22% of responsibility in cancer deaths happened in 2018. The noticed increasing prevalence of cancer is estimated to favor the growth of the global cancer immunotherapy market.
Additionally, the global cancer immunotherapy is fuelled by the high efficacy of immunotherapy compared to other treatments, fewer side effects associated with cancer immunotherapy, reduced the chance of recurrence of cancer. Some of the other notable drivers expanding the market size are technological advances in clinical therapies, an increase in the number of R&Ds for cancer treatment, and the specificity and efficacy of cancer immunotherapy to treat a wide range of cancers.
The rising adoption of advanced therapeutics for cancer and growing implementation in the healthcare sector to treat cancer diseases is also supporting the growth of the global cancer immunotherapy market. Also, public organizations are focusing on investment in Research and development activities to develop new cancer immunotherapy. The development of CAR –T cell therapy is also propelling the market growth.
MARKET RESTRAINTS:
The primary factor restraining the growth of the market is various cancer like Melanoma shows resistance to chemotherapy and radiation therapies, Cost of cancer therapies, limited information on cancer immunobiology. Furthermore, the high competition in the product development cycle is restraining the demand of the market. Depending upon the cancer types and cancer patients, it is complicated to develop a new drug with high quality, which impedes the market's demand. Also, lack of skill professional and lack of awareness among the people hamper the market growth.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2020 to 2026 |
|
Base Year |
2020 |
|
Forecast Period |
2021 to 2026 |
|
Segments Covered |
By Type of Therapies, Area of therapy, and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, Asia Pacific, Latin America, Middle East, and Africa |
This market research report on the global cancer immunotherapy market has been segmented and sub-segmented based on the type of therapies, area of therapy, and region.
Cancer Immunotherapy Market – By Type of Therapies:
Based on the type of therapies, the monoclonal antibodies segment is expected to dominate the global cancer immunotherapy market during the forecast period and had accounted leading share in 2020. The rise in monoclonal antibodies to treat a wide variety of cancers like breast cancer, lymphoma, lung cancer, brain cancer, cervical cancer, and others is the primary trend driving the market. Because of the high drug specificity towards cancer cells, this is mainly attributed to the technological superiority of this approach. These drugs are designed to identify and create a targeted immune response to cancer cells based on their proteins on the cell surface and forgo normal cells.
The monoclonal antibody segment has the most significant growth in the previous year due to high R & D investment in R&D. Some monoclonal antibodies are used for the targeted treatment of cancer. There are various types of monoclonal antibodies, such as naked, conjugated, and bispecific monoclonal antibodies. Now AbbVie product Adalimumab monoclonal antibody was the highest selling product in 2019.
Cancer Immunotherapy Market – By Area of Therapy:
Based on therapy, there is increasing use of cancer immunotherapy for melanoma therapy. Melanoma segment growth can be directly linked to new product development, many FDA approvals, and extensive research and development in this area. The U.S. FDA has recently approved three melanoma treatment checkpoint inhibitors, three cytokine therapies, and one oncolytic virus therapy.
Lung cancers had the most substantial market revenue in 2019. In 2020, the U.S. food and drug administration approved Tabrecta (Capmatinib) to treat non-small cell lung cancer. Melanoma is the fastest-growing segment due to advanced new development in the cancer immunotherapy market.
Cancer Immunotherapy Market – By Region:
Last Year, North America held the largest share of the revenue in the global cancer immunotherapy market. Increasing disease incidence, increasing accessibility to modern therapy, combined with a growing geriatric population, lead to regional market development. The North American market is further growing due to the highest cancer caused population, aged population, and modern lifestyle in the region. There is a noticeable increase in the biotechnology companies in the U.S. compared to the previous year, driving the cancer immunotherapy market in North America.
Europe has significant growth in the cancer immunotherapy market due to advanced technology and various clinical trials performed in Europe.
Throughout the forecast period, Asia Pacific is expected to experience the fastest growth. Chinese and Japan are introducing new and sophisticated immunotherapy medications. These countries have many current clinical trials for new drug molecules and alternative treatments, and FDA approvals. Approval of new treatment drugs in China and Japan is improving the tumor treatment acceptance of immunotherapy.
Recently, food and drug administration approved new technologies and implementation in China and Japan to treat small-cell lung cancer. India is driving the cancer immunotherapy market due to the vast population and genetic variation. The recent FDA approval and new drug introduction in the market are propelling the market growth.
KEY MARKET PLAYERS:
Companies leading the global cancer immunotherapy market profiled in the report are F. Hoffmann-La Roche Ltd, Amgen, Viralytics, Novartis Pharmaceuticals Corporation, Pfizer, GlaxoSmithKline Pharmaceuticals Limited, AstraZeneca plc, Medivation, Advaxis, Bristol-Myers Squibb, Merck & Co, Celgene Corp, and Immunomedics.
SOME OF THE MOST RECENT HAPPENINGS IN THIS MARKET IN THE RECENT PAST:
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Application
5.1.1 Introduction
5.1.2 Breast
5.1.3 Lung
5.1.4 Melanoma
5.1.5 Colorectal
5.1.6 Head & Neck
5.1.7 Prostate
5.1.8 Others
5.1.9 Y-o-Y Growth Analysis, By Application
5.1.10 Market Attractiveness Analysis, By Application
5.1.11 Market Share Analysis, By Application
5.2 Product Type
5.2.1 Introduction
5.2.2 Monoclonal Antibodies
5.2.3 Checkpoint inhibitors/immune modulators
5.2.4 Therapeutic cancer vaccines
5.2.5 Oncolytic virus immunotherapy
5.2.6 Cytokines
5.2.7 Adoptive T cell transfer
5.2.8 Adjuvant Immunotherapy
5.2.9 Interferons
5.2.10 Interleukins
5.2.11 BCG
5.2.12 Others
5.2.13 Y-o-Y Growth Analysis, By Product Type
5.2.14 Market Attractiveness Analysis, By Product Type
5.2.15 Market Share Analysis, By Product Type
5.3 Mode of Administration
5.3.1 Introduction
5.3.2 Intravenous
5.3.3 Oral
5.3.4 Topical
5.3.5 Intra Vesical
5.3.6 Y-o-Y Growth Analysis, By Mode of Administration
5.3.7 Market Attractiveness Analysis, By Mode of Administration
5.3.8 Market Share Analysis, By Mode of Administration
5.3 End users
5.3.1 Introduction
5.3.2 Hospitals
5.3.3 Clinics
5.3.4 Y-o-Y Growth Analysis, By End users
5.3.5 Market Attractiveness Analysis, By End users
5.3.6 Market Share Analysis, By End users
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Application
6.1.3.3 By Product Type
6.1.3.4 By Mode of Administration
6.1.3.5 By End users
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Application
6.1.4.3 By Product Type
6.1.4.4 By Mode of Administration
6.1.4.5 By End users
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Application
6.1.5.3 By Product Type
6.1.5.4 By Mode of Administration
6.1.5.6 By End users
6.2 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.3 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.4 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 South Korea
6.5 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.4.5 Rest of Latin America
6.6 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 F. Hoffmann-La Roche Ltd
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Amgen
8.3 Viralytics
8.4 Novartis Pharmaceuticals Corporation
8.5 Pfizer
8.6 GlaxoSmithKline Pharmaceuticals Limited
8.7 AstraZeneca plc
8.8 Medivation
8.9 Advaxis
8.10 Bristol-Myers Squibb
8.11 Merck & Co. and Celgene Corp
8.12 Immunomedics
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
